StockDuty ← Dashboard Jun 30, 2026 06:18 PM ET
CatalystFDA/Bio

UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA

Second CRL for hyperphosphatemia treatment OLC triggers sharp Unicycive stock decline.

What changed
Why it matters
Second CRL for hyperphosphatemia treatment OLC triggers sharp Unicycive stock decline.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →IONIS PHARMACEUTICALS, INC. (IONS) DISCUSSES FDA APPROVAL OF TRYNGOLZA FOR SEVERE HYPERTRIGLYCERIDEMIA AND ACUTE PANCREA →